Tesamorelin is gaining popularity in biohacking and body composition optimization circles due to its ability to stimulate natural growth hormone (GH) production, reduce visceral fat, support lean muscle mass, and improve metabolic functions without the need for direct exogenous GH administration. Although tesamorelin is FDA-approved solely for the treatment of HIV-associated lipodystrophy and not for bodybuilding or performance enhancement, clinical studies show it can significantly improve body composition by reducing deep abdominal fat while concurrently supporting muscle quality and metabolic health [1–6]. For this reason, the topic of „Tesamorelin in biohacking” is becoming increasingly popular among individuals interested in longevity, recovery, and metabolic optimization.
Tesamorelin functions as a stabilized analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to increase the secretion of endogenous GH, which subsequently elevates insulin-like growth factor-1 (IGF-1) levels [1,2]. Unlike direct injections of recombinant growth hormone, tesamorelin acts through the body's own hormonal signaling system, supporting a more physiological, pulsatile release of GH. Increased GH and IGF-1 activity contribute to enhanced lipolysis, improved protein synthesis, mitochondrial activity, tissue regeneration, and metabolic regulation, explaining why tesamorelin is frequently analyzed in protocols related to body recomposition and recovery [1–4].
One of the main reasons for the interest in tesamorelin in biohacking and body composition improvement is the strong clinical evidence regarding the reduction of visceral adipose tissue (VAT). Visceral fat is deep abdominal fat associated with metabolic disorders, insulin resistance, inflammation, and poor body composition. In a pooled analysis of Phase III studies involving HIV-positive individuals with excess abdominal fat, Falutz et al. (2010) demonstrated that tesamorelin reduced VAT by approximately 15.4% over 26 weeks, while simultaneously improving triglyceride levels and cholesterol ratios [3]. Long-term studies further demonstrated that the reduction in abdominal fat could persist for up to 52 weeks with continued therapy [4]. Unlike many weight-loss methods that reduce both visceral and subcutaneous fat in a non-selective manner, tesamorelin appears to preferentially target metabolically harmful visceral fat while preserving subcutaneous tissue and lean body mass.
Tesamorelin has also shown effects related to improved muscle quality and regeneration. Adrian et al. (2019) analyzed participants in clinical trials with tesamorelin and reported a significant increase in muscle density and muscle cross-sectional area in individuals who achieved a significant reduction in visceral fat [5]. Improvement was observed in several trunk muscle groups, suggesting a beneficial effect on muscle quality and lean tissue preservation. As GH and IGF-1 signaling influences collagen synthesis, protein turnover, tissue regeneration, and cellular repair, tesamorelin is often discussed in biohacking circles in the context of training recovery, body recomposition, and healthy physical aging.
Another important aspect of body composition optimization related to tesamorelin is liver health and metabolic function. Stanley et al. (2014) demonstrated that tesamorelin significantly reduced both visceral fat and hepatic fat in HIV-positive individuals with abdominal fat accumulation [6]. In the case of HIV-associated non-alcoholic fatty liver disease (NAFLD), Stanley et al. (2019) subsequently reported a relative reduction in hepatic fat of approximately 37% after 12 months of therapy [7]. Fourman et al. (2020) further demonstrated that tesamorelin improved the expression of genes associated with mitochondrial function, oxidative phosphorylation, and lipid metabolism, while simultaneously reducing inflammatory pathways and liver fibrosis [8]. Improvements in liver function and mitochondrial energy production are often considered an important component of metabolic optimization and longevity strategies.
Tesamorelin also showed a potential impact on energy metabolism and recovery ability. Makimura et al. (2014) demonstrated that tesamorelin-induced IGF-1 increase was associated with improved phosphocreatine recovery and mitochondrial function in obese adults with reduced GH secretion [9]. Improved mitochondrial efficiency may contribute to enhanced post-exercise recovery, more effective energy utilization, greater metabolic flexibility, and overall physical resilience.
Unlike anabolic steroids or direct GH therapy, tesamorelin typically results in a more moderate and physiological increase in GH and IGF-1 levels. Clinical trials have repeatedly demonstrated increased IGF-1 while maintaining relatively stable fasting glucose and HbA1c levels in most participants [3,6,7]. However, because tesamorelin activates the GH–IGF-1 axis, there can still be adverse events associated with increased GH activity. The most commonly reported include:
- Injection site reactions,
- water retention and mild swelling,
- joint pain or stiffness,
- Muscle discomfort,
- mild tingling,
- sporadic glucose tolerance disorders or slight changes in blood glucose levels [1,3,4].
Due to these hormonal effects, monitoring IGF-1 levels and metabolic markers is usually recommended during therapy.
In discussions about biohacking and bodybuilding, tesamorelin is often compared to other GH secretagogues like CJC-1295, Ipamorelin, Sermorelin, or MK-677. However, tesamorelin stands out from these substances due to extensive clinical data in humans confirming reductions in visceral and liver fat, along with measurable improvements in metabolic parameters [3–8]. Many other peptides used for „GH optimization” rely more on anecdotal evidence, experimental applications, or small pharmacokinetic studies rather than large randomized controlled trials.
In summary, tesamorelin appears most useful for optimizing body composition focused on visceral fat reduction, improving metabolic health, preserving lean tissue, and supporting recovery, rather than for extreme muscle hypertrophy or rapid weight gain. Current evidence suggests tesamorelin may improve abdominal fat distribution, reduce liver fat, enhance muscle quality, support mitochondrial function, and aid regenerative processes by physiologically activating endogenous GH and IGF-1 signaling. Despite growing interest in biohacking and physique enhancement circles, tesamorelin remains a prescription medication indicated for specific medical conditions and has not been officially approved for bodybuilding or performance enhancement purposes.
Disclaimer
The content is purely educational and scientific-informational and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or promotion of the use of performance-enhancing drugs. Tesamorelin is an FDA-approved prescription medication for specific medical indications and has not been officially approved for bodybuilding, biohacking, or physique enhancement. Hormone therapies affecting growth hormone and IGF-1 pathways may carry risks and should only be used under the supervision of a qualified healthcare professional with appropriate laboratory monitoring and individual medical assessment.
References
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
- PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Adrian, S., Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue tesamorelin reduces fat and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
- Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Fourman, L. T., Billingsley, J. M., Agyapong, G., Ho Sui, S. J., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Corey, K. E., Torriani, M., Kleiner, D. E., Hadigan, C. M., Stanley, T. L., Chung, R. T., & Grinspoon, S. K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
- Makimura, H., Murphy, C. A., Feldpausch, M. N., & Grinspoon, S. K. (2014). Effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. The Journal of Clinical Endocrinology & Metabolism, 99(1), 338–343. https://doi.org/10.1210/jc.2013-3436